XBiotech Inc. (XBIT)
Chart Events
Performance Outlook
| Previous Close | 5.63 |
| Open | 5.70 |
| Bid | 5.50 x 2900 |
| Ask | 9.94 x 900 |
| Day's Range | 5.50 - 5.87 |
| 52 Week Range | 5.09 - 18.46 |
| Volume | |
| Avg. Volume | 145,538 |
| Market Cap | 176.012M |
| Beta (5Y Monthly) | 1.44 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.43 |
| Earnings Date | Mar 14, 2022 - Mar 18, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | Jul 15, 2021 |
| 1y Target Est | N/A |
- GlobeNewswire
XBiotech Announces Successful Completion of Phase I portion of Pancreatic Cancer Study
Novel Natrunix Treatment Shows Promise in Combination Chemotherapy for Treatment of Pancreatic CancerAUSTIN, Texas, June 20, 2022 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) announced today it successfully completed the Phase I portion of its 1-BETTER study, a Phase I/II randomized, double-blind, placebo-controlled clinical study to evaluate its anti-cancer drug Natrunix in combination with chemotherapy for treating pancreatic cancer. Enrollment in the Phase II portion is commencing immedia
- Simply Wall St.
Could The XBiotech Inc. (NASDAQ:XBIT) Ownership Structure Tell Us Something Useful?
The big shareholder groups in XBiotech Inc. ( NASDAQ:XBIT ) have power over the company. Generally speaking, as a...
- GlobeNewswire
XBiotech Announces French National Agency (ANSM) Approval and National Cancer Institute (INSA) funding to Support Phase I/II/III Clinical Study for Natrunix™ in Combination with Trifluridine/Tipiracil (TASKIN) for Treatment of Metastatic Colorectal Cancer
ANSM approves NATRUNIX for INSA funded Phase-I-III Study at 20 Leading Medical Centers in FranceAUSTIN, Texas, April 28, 2022 (GLOBE NEWSWIRE) -- XBiotech (NASDAQ: XBIT) announced today that the French National Agency for the Safety of Medicines and Health Products [L'Agence nationale de sécurité du médicament et des produits de santé (ANSM)] approved the launch of a multicenter randomized clinical study for XBiotech’s candidate cancer treatment Natrunix in combination with trifluridine/tipiraci
